FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4293740050> ?p ?o ?g. }

• W4293740050 endingPage "5790" @default.
• W4293740050 startingPage "5781" @default.
• W4293740050 abstract "The global burden of malaria remains substantial. Circumsporozoite protein (CSP) has been demonstrated to be an effective target antigen, however, improvements that offer more efficacious and more durable protection are still needed. In support of research and development of next-generation malaria vaccines, Walter Reed Army Institute of Research (WRAIR) has developed a CSP-based antigen (FMP013) and a novel adjuvant ALFQ (Army Liposome Formulation containing QS-21). We present a single center, open-label, dose-escalation Phase 1 clinical trial to evaluate the safety and immunogenicity of the FMP013/ALFQ malaria vaccine candidate. In this first-in-human evaluation of both the antigen and adjuvant, we enrolled ten subjects; five received 20 μg FMP013 / 0.5 mL ALFQ (Low dose group), and five received 40 μg FMP013 / 1.0 mL ALFQ (High dose group) on study days 1, 29, and 57. Adverse events and immune responses were assessed during the study period. The clinical safety profile was acceptable and there were no serious adverse events. Both groups exhibited robust humoral and cellular immunological responses, and compared favorably with historical responses reported for RTS,S/AS01. Based on a lower reactogenicity profile, the 20 μg FMP013 / 0.5 mL ALFQ (Low dose) was selected for follow-on efficacy testing by controlled human malaria infection (CHMI) with a separate cohort. Trial Registration: Clinicaltrials.gov Identifier NCT04268420 (Registered February 13, 2020)" @default.
• W4293740050 created "2022-08-31" @default.
• W4293740050 creator A5000754492 @default.
• W4293740050 creator A5002574698 @default.
• W4293740050 creator A5003506474 @default.
• W4293740050 creator A5005601710 @default.
• W4293740050 creator A5007055020 @default.
• W4293740050 creator A5008165819 @default.
• W4293740050 creator A5012822305 @default.
• W4293740050 creator A5014264036 @default.
• W4293740050 creator A5015064780 @default.
• W4293740050 creator A5019474861 @default.
• W4293740050 creator A5021374623 @default.
• W4293740050 creator A5024492064 @default.
• W4293740050 creator A5025778635 @default.
• W4293740050 creator A5026600124 @default.
• W4293740050 creator A5029599892 @default.
• W4293740050 creator A5038837596 @default.
• W4293740050 creator A5040239230 @default.
• W4293740050 creator A5050246098 @default.
• W4293740050 creator A5050338720 @default.
• W4293740050 creator A5064194128 @default.
• W4293740050 creator A5070604419 @default.
• W4293740050 creator A5076380897 @default.
• W4293740050 creator A5084564556 @default.
• W4293740050 creator A5090960821 @default.
• W4293740050 date "2022-09-01" @default.
• W4293740050 modified "2023-10-15" @default.
• W4293740050 title "First-in-human assessment of safety and immunogenicity of low and high doses of Plasmodium falciparum malaria protein 013 (FMP013) administered intramuscularly with ALFQ adjuvant in healthy malaria-naïve adults" @default.
• W4293740050 cites W1631727505 @default.
• W4293740050 cites W2010207831 @default.
• W4293740050 cites W2017407544 @default.
• W4293740050 cites W2037900651 @default.
• W4293740050 cites W2049580315 @default.
• W4293740050 cites W2050608587 @default.
• W4293740050 cites W2053948426 @default.
• W4293740050 cites W2054347139 @default.
• W4293740050 cites W2056401826 @default.
• W4293740050 cites W2063122125 @default.
• W4293740050 cites W2069455668 @default.
• W4293740050 cites W2093112138 @default.
• W4293740050 cites W2098795075 @default.
• W4293740050 cites W2129986233 @default.
• W4293740050 cites W2163861382 @default.
• W4293740050 cites W2164153211 @default.
• W4293740050 cites W2167823105 @default.
• W4293740050 cites W2180513997 @default.
• W4293740050 cites W2289977218 @default.
• W4293740050 cites W2327361555 @default.
• W4293740050 cites W2340524139 @default.
• W4293740050 cites W2414241210 @default.
• W4293740050 cites W2436449558 @default.
• W4293740050 cites W2470897144 @default.
• W4293740050 cites W2472994826 @default.
• W4293740050 cites W2595275260 @default.
• W4293740050 cites W2605491919 @default.
• W4293740050 cites W2623747941 @default.
• W4293740050 cites W2737108166 @default.
• W4293740050 cites W2744836284 @default.
• W4293740050 cites W2898154893 @default.
• W4293740050 cites W2903409538 @default.
• W4293740050 cites W2947693660 @default.
• W4293740050 cites W2991415971 @default.
• W4293740050 cites W2996318784 @default.
• W4293740050 cites W3013273499 @default.
• W4293740050 cites W3044633595 @default.
• W4293740050 cites W3125872398 @default.
• W4293740050 cites W3134986627 @default.
• W4293740050 cites W3158165973 @default.
• W4293740050 cites W3159930662 @default.
• W4293740050 cites W3193448724 @default.
• W4293740050 cites W3203327071 @default.
• W4293740050 cites W4238512975 @default.
• W4293740050 doi "https://doi.org/10.1016/j.vaccine.2022.08.048" @default.
• W4293740050 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36055874" @default.
• W4293740050 hasPublicationYear "2022" @default.
• W4293740050 type Work @default.
• W4293740050 citedByCount "10" @default.
• W4293740050 countsByYear W42937400502022 @default.
• W4293740050 countsByYear W42937400502023 @default.
• W4293740050 crossrefType "journal-article" @default.
• W4293740050 hasAuthorship W4293740050A5000754492 @default.
• W4293740050 hasAuthorship W4293740050A5002574698 @default.
• W4293740050 hasAuthorship W4293740050A5003506474 @default.
• W4293740050 hasAuthorship W4293740050A5005601710 @default.
• W4293740050 hasAuthorship W4293740050A5007055020 @default.
• W4293740050 hasAuthorship W4293740050A5008165819 @default.
• W4293740050 hasAuthorship W4293740050A5012822305 @default.
• W4293740050 hasAuthorship W4293740050A5014264036 @default.
• W4293740050 hasAuthorship W4293740050A5015064780 @default.
• W4293740050 hasAuthorship W4293740050A5019474861 @default.
• W4293740050 hasAuthorship W4293740050A5021374623 @default.
• W4293740050 hasAuthorship W4293740050A5024492064 @default.
• W4293740050 hasAuthorship W4293740050A5025778635 @default.
• W4293740050 hasAuthorship W4293740050A5026600124 @default.
• W4293740050 hasAuthorship W4293740050A5029599892 @default.
• W4293740050 hasAuthorship W4293740050A5038837596 @default.
• W4293740050 hasAuthorship W4293740050A5040239230 @default.

• next